Company: RGBP
Filing Date: 2025-02-24
Form Type: 253G1
Source: 0001493152-25-008067
Chunk: 88

Company: Regen BioPharma Inc
Filing Date: 2025-02-24
Form: 253G1
Chunk 88
---
     |            |     |   |
|                     |     | La Mesa CA 91942                      |     |                                           |     |     |            |     |   |
| Series AA Preferred |     | All Officers and Directors as a Group |     |                                           | 334 |     |            | 100 | % |

based on 15,007 shares outstanding

| Title of Class      |     | Name and Address of Beneficial Owner  |     | Amount and Nature of Beneficial Ownership |        |     | Percentage |     |   |
| Series NC Preferred |     | David R. Koos                         |     |                                           |        |     |            |     |   |
|                     |     | c/o Regen Biopharma, Inc.             |     |                                           | 15,007 |     |            | 100 | % |
|                     |     | 4700 Spring Street St 304             |     |                                           |        |     |            |     |   |
|                     |     | La Mesa CA 91942                      |     |                                           |        |     |            |     |   |
| Series NC Preferred |     | All Officers and Directors as a Group |     |                                           | 15,007 |     |            | 100 | % |

| 65 |

SALES OF UNREGISTERED SECURITIES

October 1, 2024 to November 20, 2024

On November 4, 2024
the Company issued 500,000 common shares in settlement of $20,000 of outstanding principal indebtedness. .

The abovementioned securities were issued pursuant to Section 4(a) (2) of the securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The securities were sold directly through our management. No commission or other consideration was paid in connection with the sale of the securities. There was no advertisement or general solicitation made in connection with this Offer and Sale of securities.

On November 13, 2024 the Company issued 370,084 common shares as consideration for nonemployee services.

The abovementioned securities were issued pursuant to Section 4(a) (2) of the securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The securities were sold directly through our management. No commission or other consideration was paid in connection with the sale of the securities